AI in drug discovery is overhyped: examples from AstraZeneca, Harvard, Stanford

Re:AI in drug discovery is overhyped: examples from AstraZen... by fnl on Saturday January 06, 2018 @06:24AM (#16084790)

You call your problems "low hanging fruit", yet they are real problems that multi-billion dollar enterprises are facing and know of. If they really were as "low hanging" as you say, don't you think they'd have the resources and capacities to already have solved them? (Looking at you, Watson...)

[ Parent | on HN ]

Re:AI in drug discovery is overhyped: examples from AstraZen... by technics256 on Sunday January 07, 2018 @05:50AM (#16090324)

They are, but you have to realize that the companies themselves are focused on healthcare first, and reimbursement. Healthcare in the United States is a fee for service model, not a value based one. So the system isn't aligned for it. But they are doing it, look at the sepsis NLP solution created by Mass General in-house.

[ Parent | on HN ]